VECTIBIX Drug Profile
✉ Email this page to a colleague
Summary for Tradename: VECTIBIX
| Patents: | 2 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for VECTIBIX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VECTIBIX |
Recent Clinical Trials for VECTIBIX
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Academic and Community Cancer Research United | Phase 2 |
| Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Tesaro, Inc. | Phase 2 |
Recent Litigation for VECTIBIX
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| AbbVie Inc. v. Alvotech hf. | 2021-05-28 |
| Alvotech USA Inc. v. Abbvie Inc | 2021-05-11 |
| Ravgen, Inc. v. Illumina, Inc. | 2020-12-02 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| GEMoaB Monoclonals GmbH | 2019-12-20 |
| 2018-03-20 | |
| Forty Seven, Inc. | 2018-01-08 |
Pharmacology for VECTIBIX
| Mechanism of Action | HER1 Antagonists |
| Established Pharmacologic Class | Epidermal Growth Factor Receptor Antagonist |
| Chemical Structure | Antibodies, Monoclonal |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for VECTIBIX Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for VECTIBIX Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | See Plans and Pricing | 2039-02-26 | Company disclosures |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | See Plans and Pricing | 2017-05-05 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for VECTIBIX Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | See Plans and Pricing | 2033-03-11 | Patent claims search |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | See Plans and Pricing | 2030-04-21 | Patent claims search |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | See Plans and Pricing | 2039-02-26 | Patent claims search |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | See Plans and Pricing | 2031-01-11 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for VECTIBIX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2008273986 | See Plans and Pricing |
| South Korea | 20010012243 | See Plans and Pricing |
| Japan | 2009051861 | See Plans and Pricing |
| Japan | 3757986 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VECTIBIX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122008000028 | Germany | See Plans and Pricing | PRODUCT NAME: PANITUMUMAB MIT EINEM ANTINEOPLASTISCHEN WIRKSTOFF, INSBESONDERE PANITUMUMAB MIT EINEM ODER MEHREREN DER FOLGENDEN 1 BIS 22: 1 IRINOTECAN 2 CISPLATIN 3 5-FLUORURACIL 4 FOLINSAEURE 5 CISPNSAEURE, 5-FLUORURACIL UND IRINOTECAN =FOLFIRI 9 FOLINSAEURE, 5-FLUORURACIL UND OXALI; REGISTRATION LATIN UND/ODER DOCETAXEL 6 OXALIPLATIN UND/ODER CAPECITABIN 7 IRINOTECAN UND/ODER CYCLOSPORIN 8 FOLINO/DATE: EU/1/07/423/001-003 20071203 |
| 91411 | Luxembourg | See Plans and Pricing | 91411, EXPIRES: 20221203 |
| C00979246/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: PANITUMUMABUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 57872 14.10.2008 |
| SPC005/2008 | Ireland | See Plans and Pricing | SPC005/2008: 20081105, EXPIRES: 20221202 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
